Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
暂无分享,去创建一个
J. Burchenal | P. Armstrong | C. Granger | K. Mahaffey | J. Hochman | P. Théroux | T. Luong | J. Nicolau | S. Rollins | J. Lavoie | K. Malloy | P. Théroux